# DuPont de Nemours, Inc. (DD)

> Source: Nexqual · https://nexqual.com/DD · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, DuPont de Nemours, Inc. (DD), nexqual.com/DD" · informational, not investment advice.

**Price:** USD 135.1 (+0.71% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 134.15 · day 131.4–135.15 · 52w 100.02–157.98 · market cap $18.2B · NYQ

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $6.99B, net income $55.0M (0.8% margin), free cash flow $702M (SEC filings).
- Valuation: P/E 331.7x (avg 26.6x at the last 2 fiscal year-ends), net debt $1.39B.
- 2 of 80 tracked superinvestors hold DD (13F, Q2 2026): 0 new, 0 added, 2 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $13K; 1 not under a Rule 10b5-1 plan ($13K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.06 on a 1–5 scale) (18 analysts), mean target USD 165.47 (range 145–186).
- Total return with dividends: 1Y +34.7% vs S&P 500 +14.9%; 5Y +64.4% vs S&P 500 +80.3%.
- Next earnings: 2026-11-03, EPS estimate USD 1.88, revenue estimate $1.84B.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $12.6B | $13.0B | $6.61B | $6.72B | $6.85B | $6.99B |
| Gross profit | $4.59B | $4.62B | $2.17B | $2.22B | $2.36B | — |
| Net income | $6.47B | $5.87B | $423M | $703M | -$779M | $55.0M |
| EPS (diluted) | $14.92 | $14.75 | $2.82 | $5.04 | -$5.58 | — |
| Free cash flow | $1.49B | -$74.0M | $543M | $480M | $227M | $702M |
| Gross margin | 36.6% | 35.5% | 32.8% | 33.0% | 34.5% | — |
| Net margin | 51.5% | 45.1% | 6.4% | 10.5% | -11.4% | 0.8% |
| Revenue growth | -38.4% | +3.6% | -49.2% | +1.6% | +1.9% | — |
| Cash + short-term investments | $1.97B | $4.96B | $2.39B | — | — | — |
| Total debt | $10.8B | $8.45B | $7.86B | $7.17B | $3.13B | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 331.7x · P/S 2.6x · EV/Sales 2.8x · P/FCF 26.0x · P/B 1.3x · FCF yield 3.85% · Earnings yield 0.30% · Dividend yield (paid, TTM) 2.29% · Net debt $1.39B · EV $19.6B
P/E at fiscal year-ends: Dec 2024 19.0x, Dec 2023 34.2x.

## Superinvestors (SEC 13F-HR, Q2 2026)
2 of 80 tracked investors hold DD. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Hillman Capital | Hillman Capital Management | 3.71% | $5.1M | Reduced -68.0% |
| Dodge & Cox Funds | Dodge & Cox | <0.01% | $638K | Reduced -67.9% |

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-06-02 | Koch Lori | CEO | 261 | $13K | 0.1% | No | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 2.06 on a 1–5 scale), 18 analysts; mean target USD 165.47 (low 145, high 186).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-15 | RBC Capital | Target lowered | Outperform | $176 → $160 |
| 2026-10-13 | Barclays | Initiated | Overweight | $156 |
| 2026-10-09 | JP Morgan | Downgrade | Overweight → Neutral | $172 → $145 |
| 2026-10-07 | Citigroup | Target lowered | Buy | $170 → $162 |
| 2026-10-05 | UBS | Target lowered | Buy | $178 → $172 |
| 2026-08-10 | JP Morgan | Target raised | Overweight | $171 → $172 |
| 2026-08-07 | RBC Capital | Target lowered | Outperform | $180 → $176 |
| 2026-08-05 | UBS | Target raised | Buy | $175 → $178 |
| 2026-07-02 | Citigroup | Target raised | Buy | $168 → $170 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +34.7% | +64.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +34.9% | +10.4% |
| Volatility (annualized) | 29.8% | 30.0% |
| Max drawdown | -18.6% (Feb 2026→Sep 2026) | -39.8% (Jan 2022→Sep 2022) |

## Peers (Specialty Chemicals)
SQM (Sociedad Quimica y Minera S.A.) USD 56.37 -3.54% · LYB (LyondellBasell Industries NV) USD 65.37 +3.32% · IFF (International Flavors & Fragran) USD 93.83 +3.08% · PPG (PPG Industries, Inc.) USD 113.09 +2.65% · RPM (RPM International Inc.) USD 101.72 +1.84% · SSL (Sasol Ltd.) USD 17.46 +7.84%

## More
Full page: https://nexqual.com/DD · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in DD's own 10-K filed 2026-02-17 (https://www.sec.gov/Archives/edgar/data/1666700/000166670026000013/dd-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Qnity Electronics, Inc. (Q) | "•Tax Matters Agreement - entered into a Tax Matters Agreement with Qnity (the "Electronics Tax Matters Agreement")." |
| Partner | Corteva, Inc. (CTVA) | "4.Primarily related to the DWDP Separation and Distribution Agreement and Letter Agreement between Corteva and EIDP and the Electronics Separation and Distribution Agreement with Qnity." |
| Partner | EIDP, Inc. (CTA-PB) | "4.Primarily related to the DWDP Separation and Distribution Agreement and Letter Agreement between Corteva and EIDP and the Electronics Separation and Distribution Agreement with Qnity." |

Other companies that name DD in their own reports (relationship from DD's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| supplier | GRAHAM CORP (GHM) | 10-K 2026-06-08 | "A representative list of our customers include: 3M, Air Liquide, Anduril, Applied Research Laboratory at Pennsylvania State University, Aramco, Axiom Space, Bechtel Plant Machinery Inc., Blue Origin, …" |
| competitor | LAKELAND INDUSTRIES INC (LAKE) | 10-K 2026-04-16 | "Three of our competitors, DuPont, Ansell, and MSA Safety, have substantially greater financial, marketing and sales resources than we do." |
| partner | AirJoule Technologies Corp. (AIRJ) | 10-K 2026-03-31 | "Additionally, the AirJoule JV leases laboratory space at The Innovation Space in Wilmington's DuPont Experimental Station for coating formulation research, as well as a 12,000 square-foot facility in …" |
| competitor | ALPHA PRO TECH LTD (APT) | 10-K 2026-03-11 | "Our major competitors in the construction supply weatherization market are DuPont and Berry Global for housewrap and Owens Corning and GAF for synthetic roof underlayment." |
| competitor | CODEXIS, INC. (CDXS) | 10-K 2026-03-11 | "There is competition from large industrial enzyme companies, such as Novozymes and DuPont, as well as subsidiaries of larger contract research/CMOs, such as DSM-Firmenich AG, Cambrex Corporation, Lonz…" |
| partner | Caribou Biosciences, Inc. (CRBU) | 10-K 2026-03-05 | "On July 13, 2015, we entered into an Amended and Restated Collaboration and License Agreement (as amended, "Pioneer Agreement") with Pioneer (then a DuPont company) that superseded and replaced a prio…" |
| partner | Qnity Electronics, Inc. (Q) | 10-K 2026-02-26 | "In connection with the Spin-Off, we and/or certain of our subsidiaries have entered into various other agreements with DuPont and/or certain of its subsidiaries, including, but not limited to, the Tax…" |
| supplier | Huntsman CORP (HUN) | 10-K 2026-02-18 | "Our amines customers include Afton, Bayer, Chevron, DuPont, Evonik, Hipower, Infineum, Lubrizol, Quadra Chemicals and Univar." |
| partner | Corteva, Inc. (CTVA) | 10-K 2026-02-12 | "On April 1, 2019, the company entered into the Tax Matters Agreement with DuPont and Dow that allocates the responsibility for prior period consolidated taxes among Corteva, DuPont and Dow." |
| competitor | Origin Agritech LTD (SEED) | 20-F 2026-01-30 | "We also face competition from the large multinational companies, including Pioneer (DuPont), Monsanto and Syngenta." |

## Revenue by business segment (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Diversified Industrials | $963.0M | 52.9% | +3.3% |
| Healthcare & Water Technologies | $856.0M | 47.1% | +4.8% |
| Total revenue | $1.82B | 100% | — |

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Industrial Technologies | $538.0M | 29.6% | +4.9% |
| Healthcare Technologies | $473.0M | 26.0% | +6.5% |
| Building Technologies | $425.0M | 23.4% | +1.4% |
| Water Technologies | $383.0M | 21.1% | +2.7% |
| Total revenue | $1.82B | 100% | — |

## Revenue by region (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| United States | $809.0M | 44.5% | -1.3% |
| Asia Pacific | $454.0M | 25.0% | +7.1% |
| EMEA | $404.0M | 22.2% | +8.3% |
| China/Hong Kong | $198.0M | 10.9% | +7.6% |
| Other | $152.0M | 8.4% | +15.2% |
| Total revenue | $1.82B | 100% | — |
The lines above cover 110.9% of total revenue.

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $1.88 | $1.94 | -3.1% | $1.84B | 14 |
| Next quarter (ends 2026-12-31) | $1.88 | $1.82 | +3.3% | $1.82B | 13 |
| Current fiscal year (ends 2026-12-31) | $7.26 | $7.16 | +1.4% | $7.17B | 17 |
| Next fiscal year (ends 2027-12-31) | $7.99 | $7.88 | +1.3% | $7.45B | 17 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-03): ±8.0%; last 8 reports averaged ±4.5%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 35.8% | ±8.0% |
| 2026-12-18 | 56 | 31.4% | ±9.9% |
| 2027-01-15 | 84 | 29.2% | ±11.2% |
| 2027-03-19 | 147 | 30.2% | ±15.2% |
| 2027-04-16 | 175 | 30.0% | ±16.4% |
| 2027-06-17 | 237 | 31.1% | ±19.7% |
| 2027-09-17 | 329 | 31.1% | ±23.1% |